Specialised Therapeutics signs exclusive license agreement with CanariaBio for new ovarian cancer therapy

Independent biopharmaceutical company Specialised Therapeutics Asia Pte Ltd (ST) has signed a license deal with Korea-based CanariaBio Inc., acquiring the exclusive license to a new monoclonal antibody therapy for patients with ovarian cancer in Australia, New Zealand and in select Southeast Asian countries.

Related Keywords

Thailand ,New Zealand ,Malaysia ,Vietnam ,Republic Of ,Australia ,Singapore ,China ,Brunei ,Carlo Montagner ,Canariabio Inc ,Gynecologic Oncology Group Foundation ,Shenzhen Hepalink Pharmaceuticals Group Company ,Executive Officer Carlo Montagner ,Bio Chairman ,Specialised Therapeutics ,Greater China ,Monoclonal Antibody Therapy ,Ovarian Cancer ,Iopharmaceutical Company ,Anariabio Inc ,Chemotherapy Agents ,Erritories Of Australia ,Phase 3 ,Promising Therapy ,License Deal ,Regovomab ,Clinical Trial ,Dancer ,